Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US Launch


Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US LaunchMorgan Stanley expects the DEA to drop Epidiolex from Schedule I — the same level as cocaine, heroin and other illegal substances — to Schedule IV, where Xanax, Ambien and Tramadol rank. At worst, it would fall to Schedule III alongside moderately to lowly addictive drugs like codeine and anabolic steroids, Lebowitz said.